CN112955148A - Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 - Google Patents

Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 Download PDF

Info

Publication number
CN112955148A
CN112955148A CN201980072280.8A CN201980072280A CN112955148A CN 112955148 A CN112955148 A CN 112955148A CN 201980072280 A CN201980072280 A CN 201980072280A CN 112955148 A CN112955148 A CN 112955148A
Authority
CN
China
Prior art keywords
antibody
antigen
seq
binding fragment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980072280.8A
Other languages
English (en)
Other versions
CN112955148B (zh
Inventor
江瑶
王泉人
李华军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Suzhou Suncadia Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112955148A publication Critical patent/CN112955148A/zh
Application granted granted Critical
Publication of CN112955148B publication Critical patent/CN112955148B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

一种CDK4/6抑制剂联合免疫治疗在制备治疗淋巴的药物中的用途，具体为I所示化合物或其可药用盐联合抗PD‑1抗体或其抗原结合片段在制备治疗淋巴瘤的药物中的用途。该方法耐受性良好、毒性可控、抗肿瘤效果增强。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980072280.8A 2018-12-13 2019-12-12 Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 Active CN112955148B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811522265 2018-12-13
CN2018115222652 2018-12-13
PCT/CN2019/124831 WO2020119757A1 (zh) 2018-12-13 2019-12-12 Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途

Publications (2)

Publication Number Publication Date
CN112955148A true CN112955148A (zh) 2021-06-11
CN112955148B CN112955148B (zh) 2022-11-22

Family

ID=71077133

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072280.8A Active CN112955148B (zh) 2018-12-13 2019-12-12 Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途

Country Status (3)

Country Link
CN (1) CN112955148B (zh)
TW (1) TW202034925A (zh)
WO (1) WO2020119757A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023173172A1 (en) * 2022-03-17 2023-09-21 Aucentra Therapeutics Pty Ltd Use of 5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-n,4-dimethylthiazol-2-amine in combination therapies for cancer
WO2023173170A1 (en) * 2022-03-17 2023-09-21 Aucentra Therapeutics Pty Ltd Use of 4-thiazol-n-(pyridin-2-yl)pyrimidin-2-amine derivatives in combination therapies for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENG，J等: "《CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation》", 《CANCER DISCOV.》 *
GOODMAN，A等: "《PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas》", 《NATURE REVIEWS》 *

Also Published As

Publication number Publication date
WO2020119757A1 (zh) 2020-06-18
CN112955148B (zh) 2022-11-22
TW202034925A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN108601831A (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备***的药物中的用途
CA3133141A1 (en) Combined pharmaceutical composition for treating small cell lung cancer
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
CN112007162B (zh) Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备***药物中的用途
CN112168961A (zh) 治疗结直肠癌的联用药物组合物
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
CN112512580B (zh) Ezh2抑制剂与免疫检查点抑制剂联合在制备***的药物中的用途
CN111246881B (zh) Pd-1抗体用于***的用途
CN110859959A (zh) 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途
CN113491769A (zh) 药物联合
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
KR20200078483A (ko) 간암 치료를 위한 조성물 및 방법
CN110812485A (zh) 抗pd-1抗体联合化学疗法在制备***的药物中的用途
CN112439060B (zh) Pd-l1免疫疗法的新用途
CN111093703A (zh) 免疫治疗剂、核苷类抗代谢物和铂类联合在制备***的药物中的用途
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
CN114099670A (zh) 酪氨酸激酶抑制剂与抗pd-1抗体联合在制备***药物中的用途
CN110680919A (zh) Cdk4/6抑制剂联合免疫治疗在制备***的药物的用途
CN115279405A (zh) 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途
EP4056200A1 (en) Drug combination of quinoline derivative and pd-1 monoclonal antibody
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
WO2020083338A1 (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备***疾病的药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant